← Advanced Bronchoscopy

Pleurodesis: a comparison of two sclerosing agents for pleural effusions in Mozambique

IPBronch Review

🎯 Background & Rationale

  • Resource limitations: Standard sclerosing agents like talc and bleomycin are cost-prohibitive in resource-limited settings such as Mozambique.
  • Clinical necessity: Recurrent malignant pleural effusions cause severe dyspnea, making affordable chemical pleurodesis an essential palliative intervention.
  • Historical alternative: Sodium hydroxide (NaOH) was used historically as a low-cost pleural irritant, prompting this modern comparative evaluation.

👥 Study Design & Population

  • Retrospective cohort: Single-center observational study comparing pleurodesis outcomes between sodium hydroxide and bleomycin from 2002 to 2013.
  • Patient inclusion: 47 total patients with recurrent symptomatic pleural effusions (majority malignant, including Kaposi’s sarcoma and metastatic cancers) achieving 100% lung expansion post-thoracentesis.
  • Intervention groups: 24 patients treated with bleomycin versus 23 patients treated with 0.5% sodium hydroxide via chest tube thoracostomy.

📈 Methodology & Rigor

  • Data collection: Retrospective review of medical records at Maputo Central Hospital, evaluating baseline demographics, procedural complications, and radiographic success.
  • Statistical approach: Frequencies and proportions compared using Fisher’s exact test with a significance threshold set at P < 0.05.
  • Methodological limits: Retrospective design inherently risks selection bias, unmeasured confounding, and missing clinical records.

🔬 Key Findings [or Planned Endpoints]

  • Clinical success: No statistically significant difference in complete lung expansion or clinical success rates between sodium hydroxide and bleomycin groups.
  • General complications: General adverse events (fever, nausea, cough, dyspnea) occurred significantly less often with sodium hydroxide (10%) compared to bleomycin (38%, exact P value not detailed in text).
  • Fever incidence: Fever was reported in 0% of the sodium hydroxide group versus 23.8% of the bleomycin group (P = 0.048).
  • Recurrence rates: Only 3 patients experienced recurrent effusions requiring repeat pleurodesis, all of whom were initially treated with sodium hydroxide.
  • Cost disparity: Sodium hydroxide cost approximately $0.78 per treatment versus an average of $160 per treatment for bleomycin.

⚖️ Critical Appraisal

  • Internal validity: Small sample size (47 patients), non-randomized allocation, and retrospective data collection limit strong causal inferences.
  • External validity: Findings are derived from a single center in a developing nation with unique malignant etiologies (e.g., high burden of Kaposi’s sarcoma), limiting global generalizability.
  • Cost-effectiveness: While dramatic cost savings are evident, the lack of blinding and standardized follow-up warrants cautious interpretation of comparative efficacy.

💡 The Clinical Bottom Line

  • Resource alternative: Sodium hydroxide represents an extremely low-cost, viable alternative to bleomycin for pleurodesis in resource-limited settings.
  • Safety profile: Sodium hydroxide demonstrates comparable efficacy with potentially fewer general systemic side effects than bleomycin.
  • Future directions: Prospective, randomized trials are needed to definitively establish the safety, optimal dosing, and long-term efficacy of sodium hydroxide pleurodesis.

Abstract not available.
Read the full paper ↗

Keep reading

N opens the next one